{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rituximab&page=3", "query": { "intervention": "rituximab", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1303, "total_pages": 131, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rituximab&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rituximab&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T02:45:17.301Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00772668", "title": "Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "17 Years to 120 Years" }, "enrollment_count": 3, "start_date": "2009-09-25", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2017-12-11", "last_synced_at": "2026-10-23T02:45:17.301Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00772668" }, { "nct_id": "NCT06510309", "title": "Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Marginal Zone Lymphoma", "MZL" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gottfried von Keudell, MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2026-02-11", "completion_date": "2031-10-01", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-23T02:45:17.301Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06510309" }, { "nct_id": "NCT01594229", "title": "A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "ABT-199", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 60, "start_date": "2012-05-21", "completion_date": "2020-07-14", "has_results": false, "last_update_posted_date": "2021-08-02", "last_synced_at": "2026-10-23T02:45:17.301Z", "location_count": 8, "location_summary": "La Jolla, California • Los Angeles, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01594229" }, { "nct_id": "NCT06097364", "title": "A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma (FL)" ], "interventions": [ { "name": "Odronextamab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone/Prenisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 733, "start_date": "2023-11-14", "completion_date": "2029-07-29", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-23T02:45:17.301Z", "location_count": 9, "location_summary": "Plantation, Florida • Noblesville, Indiana • Wichita, Kansas + 6 more", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "Noblesville", "state": "Indiana" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06097364" }, { "nct_id": "NCT00577629", "title": "Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "tositumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2005-06-18", "completion_date": "2016-11-03", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-23T02:45:17.301Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00577629" }, { "nct_id": "NCT00369707", "title": "Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2006-08-09", "completion_date": "2014-10-10", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-10-23T02:45:17.301Z", "location_count": 4, "location_summary": "Miami, Florida • Chicago, Illinois • Philadelphia, Pennsylvania", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00369707" }, { "nct_id": "NCT02320292", "title": "Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ann Arbor Stage I Grade 1 Follicular Lymphoma", "Ann Arbor Stage I Grade 2 Follicular Lymphoma", "Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma", "Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma", "Ann Arbor Stage III Grade 1 Follicular Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma" ], "interventions": [ { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Yttrium Y-90 Ibritumomab Tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-02-11", "completion_date": "2023-11-09", "has_results": true, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-10-23T02:45:17.301Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02320292" }, { "nct_id": "NCT04669171", "title": "A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "EO2463", "type": "BIOLOGICAL" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Enterome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2021-07-05", "completion_date": "2034-05-30", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-10-23T02:45:17.301Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Rochester, Minnesota • Rochester, New York + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Rochester", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04669171" }, { "nct_id": "NCT01647971", "title": "Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkins Lymphoma", "B-cell Lymphoma", "Waldenstrom's Macroglobulinemia", "Marginal Zone Lymphoma", "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)", "Primary Central Nervous System Lymphoma" ], "interventions": [ { "name": "Ublituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2012-07-19", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2022-11-21", "last_synced_at": "2026-10-23T02:45:17.301Z", "location_count": 8, "location_summary": "Huntsville, Alabama • Jonesboro, Arkansas • Athens, Georgia + 5 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Athens", "state": "Georgia" }, { "city": "Macon", "state": "Georgia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01647971" }, { "nct_id": "NCT00473551", "title": "Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Radiation Treatment", "type": "RADIATION" }, { "name": "Stem Cell Transplantation (SCT)", "type": "PROCEDURE" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Anti-third Party Cytolytic T-lymphocytes (CTL)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 4, "start_date": "2007-05", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2011-12-19", "last_synced_at": "2026-10-23T02:45:17.301Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00473551" } ] }